Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Check-Cap ( (MBAI) ) has issued an update.
On December 17, 2025, Check-Cap Ltd. entered into a purchase agreement with ARC Group International Ltd. that gives the company the option, but not the obligation, to sell up to $30 million of its ordinary shares over a 36‑month period, subject to trading-volume caps, ownership and issuance limits, and the prior effectiveness of a resale registration statement. The structure, which includes a $450,000 share-based commitment fee and caps the investor’s stake below 10% and total issuance below 19.99% absent shareholder approval, provides Check-Cap with flexible, on-demand access to growth capital for working capital and general corporate purposes while limiting immediate dilution and concentration risk; the shares sold so far were issued in a private, unregistered offering to an accredited investor. Separately, on December 19, 2025, the company’s audit committee appointed BCRG Group as its new independent registered public accounting firm, replacing RBSM LLP and tasking BCRG with reviewing interim financials for the six months ended June 30, 2025 and handling all subsequent audit and review services, signaling a change in oversight of the company’s financial reporting.
Spark’s Take on MBAI Stock
According to Spark, TipRanks’ AI Analyst, MBAI is a Underperform.
Check-Cap’s overall score reflects its significant financial challenges, primarily due to a lack of revenue generation and persistent losses. While the technical analysis hints at possible recovery, the valuation is weak due to negative profitability indicators. The company’s strong equity position is a positive aspect, but without revenue, it faces substantial risks.
To see Spark’s full report on MBAI stock, click here.
More about Check-Cap
Check-Cap Ltd. is an Israel-based medical technology company that develops and markets products in the healthcare sector; its securities are listed in the United States as a foreign private issuer and it primarily accesses U.S. capital markets through registered share offerings and private placement mechanisms.
Average Trading Volume: 282,238
Technical Sentiment Signal: Hold
Current Market Cap: $13.2M
For an in-depth examination of MBAI stock, go to TipRanks’ Overview page.